TY - JOUR
T1 - Management of Locally Advanced Gastroesophageal Cancer
T2 - Still a Multidisciplinary Global Challenge?
AU - Al-Batran, Salah Eddin
AU - Lorenzen, Sylvie
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/6
Y1 - 2017/6
N2 - The outcome of patients with locally advanced, resectable gastric cancer, or adenocarcinoma of the gastroesophageal junction is poor. In clinical trials, multimodality therapy, such as perioperative chemotherapy, preoperative or postoperative chemoradiation, or adjuvant chemotherapy led to significant increments in survival. Therefore, experts agree that patients with stage II or III disease should be offered a multidisciplinary treatment approach. However, patients are treated somewhat differently in the different regions of the world and survival rates remain far from being satisfactory. Efforts to further improve outcome are highly warranted.
AB - The outcome of patients with locally advanced, resectable gastric cancer, or adenocarcinoma of the gastroesophageal junction is poor. In clinical trials, multimodality therapy, such as perioperative chemotherapy, preoperative or postoperative chemoradiation, or adjuvant chemotherapy led to significant increments in survival. Therefore, experts agree that patients with stage II or III disease should be offered a multidisciplinary treatment approach. However, patients are treated somewhat differently in the different regions of the world and survival rates remain far from being satisfactory. Efforts to further improve outcome are highly warranted.
KW - Chemotherapy
KW - Gastroesophageal cancer
KW - Locally advanced
KW - Perioperative
UR - http://www.scopus.com/inward/record.url?scp=85016556735&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2017.01.004
DO - 10.1016/j.hoc.2017.01.004
M3 - Review article
C2 - 28501086
AN - SCOPUS:85016556735
SN - 0889-8588
VL - 31
SP - 441
EP - 452
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 3
ER -
